Scynexis and Molecular Engines Laboratories of France have struck an agreement to pursue development of anti-cancer therapeutics.

Scynexis, which has its headquarters in RTP, will work with the French firm through the Scynexis operation in Cambridge, England.

Terms of the agreement were not disclosed.

The companies want to speed up identification of MEL’s cancer targets, using synthetic chemistry processes from Scynexis.